No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
J&J’s Subcutaneous Guselkumab EU Approved for Ulcerative Colitis
On 24 October 2025, Johnson & Johnson announced that the European Commission has approved a subcutaneous (SC) induction dose regimen of Tremfya® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic treatment.